The epilepsies are an important, common and diverse group of symptom complexes characterized by recurrent spontaneous seizures. Although many patients with epilepsy have their seizures controlled ...

December 9, 2010 — New study results show that 46% of patients with refractory seizures improved with adjunctive rufinamide, with most of these showing a more than 50% decline in seizure frequency.

Of course, retrospective studies lack the rigor of the blinded studies, [24] but they might provide useful insight into the efficacy of a new antiepileptic drug. In fact, a new antiepileptic drug is ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck today presented data at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. that demonstrates that the Refractory Epilepsy Screening Tool ...

Most patients suffering from epilepsy will see significant improvement with the use of medication, yet 1 in 3 patients will develop drug resistant or refractory epilepsy. According to epileptologist ...

Although several drugs in wide use at the present time benefit the majority of patients with petit-mal seizures the seizures of some patients are not controlled by commonly used medications; thus, in ...

In a small phase I and II clinical trial, researchers and colleagues elsewhere found that the high-fat, low-carbohydrate ketogenic diet was a safe and effective treatment option for the majority of ...

New Treatment Option For Epilepsy Patients With One Of The Most Debilitating Seizure Types The U.S. Food and Drug Administration (FDA) yesterday approved UCB's leading anti-epileptic drug Keppra(R) ...

Epilepsy is a non-infectious cognitive disease that is common but people are not aware about this disease. As per reports, about 70 million people are epileptic in the worldwide which confirms this as ...

NOVATO, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today ...

Neurocrine builds out its early-stage pipeline with another partnership deal, acquiring the rights to an epilepsy program from Xenon Pharmaceuticals. Xenon's sodium channel inhibitors could have broad ...